Lucid Diagnostics Inc (LUCD)

$1.50 +0.03 (2.04%)
Market Cap 133.41M
Revenue (ttm) 4.35M
Net Income (ttm) -45.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,046.67%
Debt to Equity Ratio 3.45
Volume 596,900
Avg Vol 747,504
Day's Range N/A - N/A
Shares Out 90.75M
Stochastic %K 0%
Beta 1.26
Analysts Strong Sell
Price Target $3.50

Latest News on LUCD

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 9:00 AM EDT - 15 hours ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

PAVM

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Mar 27, 2025, 8:01 AM EDT - 7 days ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PAVM

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 12:17 PM EDT - 10 days ago

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 10 days ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PAVM

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Mar 20, 2025, 8:31 AM EDT - 14 days ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

PAVM

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Mar 18, 2025, 8:31 AM EDT - 16 days ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PAVM

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Mar 13, 2025, 7:36 AM EDT - 21 days ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PAVM

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Mar 10, 2025, 9:01 AM EDT - 24 days ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PAVM

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Mar 5, 2025, 4:45 PM EST - 4 weeks ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

PAVM

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

Mar 4, 2025, 8:25 AM EST - 4 weeks ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

PAVM

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

Feb 27, 2025, 8:31 AM EST - 5 weeks ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PAVM

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 25, 2025, 8:31 AM EST - 5 weeks ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PAVM

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

Feb 20, 2025, 8:31 AM EST - 6 weeks ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

PAVM

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

Feb 18, 2025, 8:30 AM EST - 6 weeks ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

PAVM

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 6, 2025, 8:57 AM EST - 2 months ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

PAVM

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Jan 13, 2025, 7:56 AM EST - 2 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PAVM

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Dec 23, 2024, 8:01 AM EST - 3 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PAVM

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Dec 19, 2024, 8:01 AM EST - 3 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

PAVM

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Dec 11, 2024, 8:01 AM EST - 4 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

PAVM

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Dec 3, 2024, 8:01 AM EST - 4 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

PAVM

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Nov 20, 2024, 7:56 AM EST - 4 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PAVM

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Nov 18, 2024, 8:15 AM EST - 4 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVM

Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:44 PM EST - 5 months ago

Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

Nov 13, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

PAVM

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Nov 7, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PAVM

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Nov 5, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PAVM

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

Oct 30, 2024, 8:31 AM EDT - 5 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

PAVM

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

Oct 15, 2024, 7:51 AM EDT - 6 months ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PAVM

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

Oct 9, 2024, 1:46 PM EDT - 6 months ago

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

ALUR GEVO KULR

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 8:01 AM EDT - 6 months ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

PAVM

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

Oct 8, 2024, 7:49 AM EDT - 6 months ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

PAVM

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

Sep 24, 2024, 8:01 AM EDT - 6 months ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PAVM

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

Sep 16, 2024, 4:30 PM EDT - 7 months ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

PAVM

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

Sep 10, 2024, 7:56 AM EDT - 7 months ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

PAVM

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

Sep 3, 2024, 7:51 AM EDT - 7 months ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

PAVM

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

Aug 20, 2024, 8:16 AM EDT - 8 months ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PAVM

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

Aug 13, 2024, 8:16 AM EDT - 8 months ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PAVM

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

Aug 13, 2024, 8:01 AM EDT - 8 months ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

PAVM

Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 1:32 PM EDT - 8 months ago

Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

Aug 12, 2024, 8:07 AM EDT - 8 months ago

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

PAVM

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

Aug 8, 2024, 8:31 AM EDT - 8 months ago

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

PAVM

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

Aug 6, 2024, 8:15 AM EDT - 8 months ago

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

PAVM

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Aug 5, 2024, 8:15 AM EDT - 8 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVM

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

Jul 29, 2024, 8:15 AM EDT - 8 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

PAVM

Lucid Diagnostics Launches New Corporate Website

Jul 11, 2024, 8:31 AM EDT - 9 months ago

Lucid Diagnostics Launches New Corporate Website

PAVM

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

Jul 2, 2024, 7:55 AM EDT - 9 months ago

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PAVM

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

Jun 12, 2024, 8:05 AM EDT - 10 months ago

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

PAVM

PAVmed Provides Business Update and First Quarter 2024 Financial Results

May 13, 2024, 8:43 PM EDT - 11 months ago

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PAVM

Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript

May 13, 2024, 1:01 PM EDT - 11 months ago

Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

May 13, 2024, 8:00 AM EDT - 11 months ago

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

PAVM